Omeros (OMER) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- $0.10
- Estimate
- -$0.33
- Surprise
- +128.8%
- Revenue (period 2026-06-30)
- $28.5M
- Score today
- 5.7/10
Revenue source: xbrl.
How the report landed
Omeros (OMER) beat the -$0.33 estimate with diluted EPS of $0.10 — a large 128.8% upside surprise.
Coverage in the report window
- 12 Health Care Stocks Moving In Thursday's Intraday Session — benzinga, 2026-08-13
- Accelerant Holdings, CorMedix, Birkenstock And Other Big Stocks Moving Higher On Thursday — benzinga, 2026-08-13
- 12 Health Care Stocks Moving In Thursday's Pre-Market Session — benzinga, 2026-08-13
Where TrendMatrix's rating stands now
TrendMatrix currently rates OMER Sell at 5.7/10; no pre/post engine snapshot brackets this report.
4 of the last 4 quarters beat the estimate; this quarter's +128.8% surprise compares with a +111.7% four-quarter average. Next scheduled report: 2026-11-12.
What argues against it
- Concentration risk — Product: YARTEMLEA
- Concentration risk — Supplier: Lonza
- Risk below floor (2.3 < 3.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $19.19
- Price target
- $28.05
- Stop
- $17.92
- Upside to target
- +46.2%
- Reward-to-risk
- 3.0:1
Forward estimates sit below the trailing run-rate (16.8× forward vs 11.3× trailing) — consensus expects earnings to decline from here.
Risk check: RSI 92 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-08-23 — shown for context, not personalized investment advice.
OMER at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $1.39B
- P/E (fwd)
- 16.8
- P/E (ttm)
- 11.3
- 52-week range
- $3.94–$19.58
- Off 52-week high
- 2.0%
- RSI (14)
- 92
- Volume vs avg
- 1.00×
- Score today
- 5.7/10